Welcome to our dedicated page for Absci news (Ticker: ABSI), a resource for investors and traders seeking the latest updates and insights on Absci stock.
Absci Corporation develops generative AI-designed biologic therapeutics as a clinical-stage biopharmaceutical company. News about ABSI centers on its Integrated Drug Creation platform, internal prolactin and prolactin receptor (PRLR) programs, and clinical development of ABS-201, an anti-PRLR antibody being developed for androgenetic alopecia and endometriosis.
Recurring updates cover HEADLINE trial safety, tolerability and pharmacokinetic disclosures, preclinical pipeline additions such as ABS-202, business and operating results, clinical advisory activity, healthcare conference participation, executive leadership changes, and Nasdaq inducement equity grants.
Absci (Nasdaq: ABSI) announced participation in two upcoming investor conferences in June 2026. Management will present at the Jefferies Global Healthcare Conference on June 3 and the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, with live and archived webcasts on its investor relations site.
Absci (Nasdaq: ABSI) reported Q1 2026 results and program updates. ABS-201 completed four SAD cohorts and is well tolerated; preliminary PK modeling supports a targeted dosing interval of two-to-three injections over six months. MAD dosing in AGA participants has begun. ABS-202 added to preclinical pipeline. Q2 2026 preliminary data and H2 2026 interim proof-of-concept expected. Financials: revenue $0.2M, R&D $19.3M, SG&A $9.1M, net loss $29.6M, cash and equivalents $125.7M; runway into H1 2028.
Absci (Nasdaq: ABSI) granted a non-statutory option for 276,200 shares to a newly hired non-executive employee on May 1, 2026 as an inducement under its 2023 Inducement Plan pursuant to Nasdaq Listing Rule 5635(c)(4).
The option carries an exercise price of $4.92 (closing price on the Grant Date), a 10-year term, and vests 25% after one year with the remaining 75% vesting in approximately equal monthly installments over the following 36 months, subject to continued service and plan terms.
Absci (Nasdaq: ABSI) will report business updates and first quarter 2026 financial and operating results after market close on May 7, 2026. Management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT. Live audio and a replay will be available on the company investor relations website.
Absci (Nasdaq: ABSI) will participate in the 25th Annual Needham Virtual Healthcare Conference.
Management is scheduled for a fireside chat on April 16, 2026 at 1:30 p.m. ET (10:30 a.m. PT). A live and archived webcast will be available on the company's investor relations website.
Absci (Nasdaq: ABSI) reported Q4 and full-year 2025 results and operational updates including dosing three SAD cohorts of ABS-201 in the Phase 1/2a HEADLINE trial with favorable emerging safety data and human ex vivo evidence of hair-growth activity.
Cash and marketable securities were $144.3M at year-end, sufficient to fund operations into H1 2028 per the company.
Absci (NASDAQ: ABSI) launched an Endometriosis Advisory Board to guide clinical development of ABS-201, an anti‑prolactin receptor antibody designed as a non‑hormonal therapy for endometriosis. The board includes experts from Yale, UCSF, Duke, and Mayo Clinic. Absci anticipates Phase 2 start in Q4 2026 and an interim readout in H2 2027. ABS-201 is formulated for subcutaneous self-administration and showed an extended half-life in non‑human primates, aiming to treat lesions without suppressing ovulation or fertility.
Absci (Nasdaq: ABSI) granted a 650,000-share non-statutory stock option to Dr. Ransi Somaratne as an inducement for his employment as Chief Medical Officer on March 3, 2026.
The option has a $2.57 exercise price (closing price on March 3, 2026), a 10-year term, and vests over four years (25% at one year, remainder in 36 monthly installments).
Absci (Nasdaq: ABSI) appointed Ransi Somaratne, M.D., FACC, MBA as Chief Medical Officer effective March 3, 2026 to lead clinical development of its AI-designed therapeutics, including flagship ABS-201. Chief Innovation Officer Andreas Busch, Ph.D. will retire March 31, 2026 and transition to co-chair Absci’s Scientific Advisory Board.
Dr. Somaratne joins from Vertex and has prior leadership at BioMarin and Amgen, with experience on Roctavian, Repatha, and Journavx.
Absci (Nasdaq: ABSI) will report business updates and fourth-quarter and full-year 2025 financial and operating results after market close on March 24, 2026.
A webcast and live audio conference call will begin at 4:30 p.m. ET (1:30 p.m. PT), with the live stream and archived replay available via the company’s investor relations site at investors.absci.com.